CELL INTELLIGENCE · 肿瘤细胞治疗研究

INTRODUCTION: Metastatic castration-resistant prostate cancer (mCRPC) has a poor prognosis. This study evaluated the safety, immune responses, and clinical outcomes of Wilms' tumor 1 (WT1) peptide-loaded dendritic cell (DC) vaccination combined with hormone or chemotherapeutic agents in mCRPC patients. METHODS: WT1 peptide-loaded mature DCs were administered intradermally and the adjuvant OK-432 every 2-4 weeks. WT1-specific immune responses were assayed using ELISpot, HLA-tetramer, and CD107a assays. RESULTS: Vaccination was well tolerated with no severe adverse events. WT1-specific immune responses were significantly enhanced in patients with stable disease (SD), along with reduced regulatory T cells. A PSA reduction of >50% was achieved in 35.7% of patients. Median overall survival (mOS) was 28.5 months, exceeding the Halabi nomogram's estimate (19.0 months). Patients with WT1-specific immune responses exhibited significantly longer mOS, suggesting a link between WT1-specific immunity and favorable outcomes. CONCLUSION: This immunotherapy approach shows promise for improving survival in mCRPC patients.